Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.

@article{Hoeper2013RiociguatFI,
  title={Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.},
  author={Marius M Hoeper and Michael Halank and Heinrike Wilkens and Andreas G{\"u}nther and Gerrit Weimann and Irmingard Gebert and Hanno H. Leuchte and J{\"u}rgen Behr},
  journal={The European respiratory journal},
  year={2013},
  volume={41 4},
  pages={853-60}
}
We assessed the safety, tolerability and preliminary efficacy of riociguat, a soluble guanylate cyclase stimulator, in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). In this open-label, uncontrolled pilot trial, patients received oral riociguat (1.0-2.5 mg three times daily) for 12 weeks (n=22), followed by an ongoing long-term extension (interim analysis at 12 months) in those eligible (n=15). Primary end-points were safety and tolerability. Secondary… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…